UPCOMING SESSIONS in ET
Tue, Jun 9, 2026
5:00 – 6:00 AM Bangkok
What is a care team and how to build one that works for you? Elizabeth Hushka Click Here To Register
UPCOMING SESSIONS in ET
Tue, Jun 9, 2026 · 5:00 – 6:00 AM Bangkok
What is a care team and how to build one that works for you?
Elizabeth Hushka
Click Here To Register
View all sessions

News

Rare Disease Advisor
May 29, 2026
Patisiran and Vutrisiran for ATTR-PN Show No Vitamin A Deficiency Safety Risks
There were no safety findings associated with vitamin A deficiency following treatment with patisiran or vutrisiran in patients with transthyretin (TTR) amyloidosis…
Read more
amyloidosis
May 29, 2026
US bank sees positive risk-reward for AstraZeneca ahead of pivotal heart drug trial
Citi sees the risk-reward balance as favourable for AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) ahead of headline results from a pivotal trial of its heart drug…
Read more
The Columbus Dispatch
May 29, 2026
Memorial host Jack Nicklaus continues to deal with heart condition
At age 86, Jack Nicklaus no longer strolls the fairways with a bounce in his step, but age is not the only specific factor in the Golden Bear's slowdown.Nicklaus…
Read more
ResearchGate
May 28, 2026
Patient Perspectives on Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Attributes
Transthyretin amyloid cardiomyopathy (ATTR-CM), a progressive disease characterized by the accumulation of misfolded transthyretin amyloid proteins in the…
Read more
May 28, 2026
Hereditary Transthyretin Amyloidosis (hATTR) Market Trends, Innovation, and Future Growth Outlook to 2036 - DelveInsight |Alnylam Pharma, Ionis Pharma, Novo Nordisk, AstraZeneca, Pfizer, Intellia
The Key Hereditary Transthyretin Amyloidosis Companies in the market include - Alnylam Pharmaceuticals, Ionis Pharmaceuticals, AstraZeneca, Pfizer, Intellia…
Read more
amyloidosis
May 28, 2026
Earlier diagnosis, new therapies boost ATTR-CM survival rates: Review
More recent clinical trials also show less advanced disease in patientsPeople with transthyretin amyloid cardiomyopathy (ATTR-CM) enrolled in more recent…
Read more
JACC Journal
May 27, 2026
Contemporary Management of Acute Heart Failure: From Emergency Presentation to Long-Term Remission
AbstractAcute heart failure (AHF) represents a major global health challenge, with a substantial impact on survival, morbidity, and health care resource utilization…
Read more
American Heart Association Journals
May 27, 2026
Multimodal Artificial Intelligence for Cardiac Amyloidosis Diagnosis: Integrating Echocardiography With Clinical and Laboratory Data for Improved Detection
AbstractBACKGROUND:Cardiac amyloidosis (CA) is an underdiagnosed yet treatable cause of heart failure in which timely diagnosis is essential to initiate life-…
Read more
springer nature
May 27, 2026
Vutrisiran-Mediated Knockdown of Transthyretin in Patients with ATTR Amyloidosis
AbstractBackground and ObjectiveWe assessed the consistency of serum transthyretin (TTR) knockdown with the RNA interference therapeutic vutrisiran across…
Read more
Rare Disease Advisor
May 26, 2026
Patisiran and Vutrisiran for ATTR-CM Show No Vitamin A Deficiency Safety Risks
There were no safety findings associated with vitamin A deficiency following treatment with patisiran or vutrisiran in patients with transthyretin (TTR) amyloidosis…
Read more
Subscribe to